Behavioral and biochemical changes caused by muscimol in mice withdrawn from haloperidol administration

Alice Kuruvilla, Y. K. Fung, N. J. Uretsky

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

This study was designed to determine the behavioral and biochemical effects of the γ-aminobutyric acid (GABA) agonist, muscimol, in mice withdrawn from chronic haloperidol administration. Mice received either haloperidol or vehicle in their drinking water for 35 days, after which the haloperidol was replaced with vehicle. Seven days after withdrawal from chronic treatment with haloperidol, the effect of apomorphine on the climbing behavior of haloperidol-withdrawn mice was markedly enhanced as compared to control mice that received only vehicle. Muscimol produced a dose-related reduction in the intensity of climbing behavior induced by apomorphine in both control and haloperidol-withdrawn mice. However, the inhibition of climbing behavior induced by muscimol was significantly greater in haloperidol-withdrawn animals. In addition, in haloperidol-withdrawn mice, muscimol produced a significant reduction in striatal homovanillic (HVA) levels with no change in striatal dopamine (DA) levels, suggesting a decrease in DA turnover. In support of this conclusion, muscimol decreased the disappearance of dopamine in haloperidol-withdrawn mice that were injected with α-methyl-p-tyrosine. Both the behavioral and biochemical effects of muscimol were blocked by the GABA antagonist, picrotoxin. These results indicate that after chronic haloperidol administration there is not only an enhanced response to dopaminergic agonists but also to GABAergic agonists.

Original languageEnglish (US)
Pages (from-to)891-897
Number of pages7
JournalNeuropharmacology
Volume21
Issue number9
DOIs
StatePublished - Sep 1982

Fingerprint

Muscimol
Haloperidol
Corpus Striatum
Dopamine
Apomorphine
GABA Antagonists
GABA Agonists
Aminobutyrates
Picrotoxin
Dopamine Agonists
Drinking Water
Tyrosine

Keywords

  • GABA
  • climbing behavior
  • haloperidol
  • homovanillic acid
  • muscimol

ASJC Scopus subject areas

  • Pharmacology
  • Cellular and Molecular Neuroscience

Cite this

Behavioral and biochemical changes caused by muscimol in mice withdrawn from haloperidol administration. / Kuruvilla, Alice; Fung, Y. K.; Uretsky, N. J.

In: Neuropharmacology, Vol. 21, No. 9, 09.1982, p. 891-897.

Research output: Contribution to journalArticle

Kuruvilla, Alice ; Fung, Y. K. ; Uretsky, N. J. / Behavioral and biochemical changes caused by muscimol in mice withdrawn from haloperidol administration. In: Neuropharmacology. 1982 ; Vol. 21, No. 9. pp. 891-897.
@article{8a2ed46776724595859066575f44ed7e,
title = "Behavioral and biochemical changes caused by muscimol in mice withdrawn from haloperidol administration",
abstract = "This study was designed to determine the behavioral and biochemical effects of the γ-aminobutyric acid (GABA) agonist, muscimol, in mice withdrawn from chronic haloperidol administration. Mice received either haloperidol or vehicle in their drinking water for 35 days, after which the haloperidol was replaced with vehicle. Seven days after withdrawal from chronic treatment with haloperidol, the effect of apomorphine on the climbing behavior of haloperidol-withdrawn mice was markedly enhanced as compared to control mice that received only vehicle. Muscimol produced a dose-related reduction in the intensity of climbing behavior induced by apomorphine in both control and haloperidol-withdrawn mice. However, the inhibition of climbing behavior induced by muscimol was significantly greater in haloperidol-withdrawn animals. In addition, in haloperidol-withdrawn mice, muscimol produced a significant reduction in striatal homovanillic (HVA) levels with no change in striatal dopamine (DA) levels, suggesting a decrease in DA turnover. In support of this conclusion, muscimol decreased the disappearance of dopamine in haloperidol-withdrawn mice that were injected with α-methyl-p-tyrosine. Both the behavioral and biochemical effects of muscimol were blocked by the GABA antagonist, picrotoxin. These results indicate that after chronic haloperidol administration there is not only an enhanced response to dopaminergic agonists but also to GABAergic agonists.",
keywords = "GABA, climbing behavior, haloperidol, homovanillic acid, muscimol",
author = "Alice Kuruvilla and Fung, {Y. K.} and Uretsky, {N. J.}",
year = "1982",
month = "9",
doi = "10.1016/0028-3908(82)90081-8",
language = "English (US)",
volume = "21",
pages = "891--897",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",
number = "9",

}

TY - JOUR

T1 - Behavioral and biochemical changes caused by muscimol in mice withdrawn from haloperidol administration

AU - Kuruvilla, Alice

AU - Fung, Y. K.

AU - Uretsky, N. J.

PY - 1982/9

Y1 - 1982/9

N2 - This study was designed to determine the behavioral and biochemical effects of the γ-aminobutyric acid (GABA) agonist, muscimol, in mice withdrawn from chronic haloperidol administration. Mice received either haloperidol or vehicle in their drinking water for 35 days, after which the haloperidol was replaced with vehicle. Seven days after withdrawal from chronic treatment with haloperidol, the effect of apomorphine on the climbing behavior of haloperidol-withdrawn mice was markedly enhanced as compared to control mice that received only vehicle. Muscimol produced a dose-related reduction in the intensity of climbing behavior induced by apomorphine in both control and haloperidol-withdrawn mice. However, the inhibition of climbing behavior induced by muscimol was significantly greater in haloperidol-withdrawn animals. In addition, in haloperidol-withdrawn mice, muscimol produced a significant reduction in striatal homovanillic (HVA) levels with no change in striatal dopamine (DA) levels, suggesting a decrease in DA turnover. In support of this conclusion, muscimol decreased the disappearance of dopamine in haloperidol-withdrawn mice that were injected with α-methyl-p-tyrosine. Both the behavioral and biochemical effects of muscimol were blocked by the GABA antagonist, picrotoxin. These results indicate that after chronic haloperidol administration there is not only an enhanced response to dopaminergic agonists but also to GABAergic agonists.

AB - This study was designed to determine the behavioral and biochemical effects of the γ-aminobutyric acid (GABA) agonist, muscimol, in mice withdrawn from chronic haloperidol administration. Mice received either haloperidol or vehicle in their drinking water for 35 days, after which the haloperidol was replaced with vehicle. Seven days after withdrawal from chronic treatment with haloperidol, the effect of apomorphine on the climbing behavior of haloperidol-withdrawn mice was markedly enhanced as compared to control mice that received only vehicle. Muscimol produced a dose-related reduction in the intensity of climbing behavior induced by apomorphine in both control and haloperidol-withdrawn mice. However, the inhibition of climbing behavior induced by muscimol was significantly greater in haloperidol-withdrawn animals. In addition, in haloperidol-withdrawn mice, muscimol produced a significant reduction in striatal homovanillic (HVA) levels with no change in striatal dopamine (DA) levels, suggesting a decrease in DA turnover. In support of this conclusion, muscimol decreased the disappearance of dopamine in haloperidol-withdrawn mice that were injected with α-methyl-p-tyrosine. Both the behavioral and biochemical effects of muscimol were blocked by the GABA antagonist, picrotoxin. These results indicate that after chronic haloperidol administration there is not only an enhanced response to dopaminergic agonists but also to GABAergic agonists.

KW - GABA

KW - climbing behavior

KW - haloperidol

KW - homovanillic acid

KW - muscimol

UR - http://www.scopus.com/inward/record.url?scp=0019977496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019977496&partnerID=8YFLogxK

U2 - 10.1016/0028-3908(82)90081-8

DO - 10.1016/0028-3908(82)90081-8

M3 - Article

C2 - 6890637

AN - SCOPUS:0019977496

VL - 21

SP - 891

EP - 897

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

IS - 9

ER -